Virus specific antibody - based remedies for the urgent prevention and treatment of Ebola virus disease


Cite item

Full Text

Abstract

The Ebola virus (member of Ebolavirus genus Filoviridae family) is the etiologic agent of extremely hazard human disease with high mortality rates (up to 90%). The most important components of spectrum of therapeutics for special prophylactic and current of disease, caused by Ebola virus, are prepares, based on virus specific antibodies (convalescent’s plasma, geterologic immunoglobulins, monoclonal antibodies. The use of different class therapeutics, based on virus specific antibodies, the possible improvements of its composition and strategy of its application for special prophylactic and current of disease, caused by Ebola virus, are considered in this review.

About the authors

T E Sizikova

48 Central Scientific Research Institute

к.б.н., н. с. ФГБУ «48 ЦНИИ» МО России, ORCID: 0000-0002-1817-0126 Sergiev Posad, Russia

V N Lebedev

48 Central Scientific Research Institute

д.б.н., проф., в.н.с. ФГБУ «48 ЦНИИ» МО России, ORCID: 0000-0002-6552-4599 Sergiev Posad, Russia

S V Borisevich

48 Central Scientific Research Institute

Email: 48cnii@mil.ru
д.б.н., проф., член-корр. РАН, начальник ФГБУ «48 ЦНИИ» МО России, тел.: 8(496)552-12-06; e-mail: 48cnii@mil.ru; ORCID: 0000-0002-5742-3919 Sergiev Posad, Russia

References

  1. Эпидемиология, профилактика и лабораторная диагностика болезни, вызванной вирусом Эбола. Практическое руководство. Под ред. Поповой А.Ю., Кутырева В.В. Саратов: Буква, 2015: 244 с.
  2. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow M.S. Emergence of Zaire Ebola Virus Disease in Guinea. New Eng J Med. 2014;378:1418-25. https://doi.org/10.1056/NEJMoa1404505
  3. Li J, Duan H.J, Chen H.Y, et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis. 2016;42:34-9. https://doi.org/ 10.1016/j.ijid.2015.10.021
  4. WHO URL: http://apps.who.int/gho/data/node.ebola-sitrep
  5. Emond R.T, Evans B, Bowen E.T, Lloyd G. A case of Ebola virus infection. Br Med J. 1977;2(6086):541-4. PMID: 890413
  6. Mupapa K, Massambla M, Ribadi K. Treatment of Ebola virus hemorrhagic fever with.blood transfusions from convalescent patients. J Infect Dis. 1999;179(1):18-23. https://doi.org/10.1086/514298
  7. Van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. New Eng J Med. 2016;374(1):33-42. https://doi.org/ 10.1056/nejmoa1511812
  8. Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428-35. https://doi.org/10.1016/S0140-6736(14)62384-9
  9. Uyeki T.M, Mehta A.K, Davey R.T, et al. Clinical Management of Ebola Virus Disease in the United States and Europe. New Eng J Med. 2016;374(7):636-46. https://doi.org/10.1056/ nejmoa1504874
  10. Маркин В.А., Михайлов В.В., Краснянский В.П., Борисевич И.В., Фирсова И.В. Разработка принципов экстренной профилактики и лечения лихорадки Эбола. Вопросы вирусологии. 1997;42(1):31-4.
  11. Dowall S.D, Rayner E, Hall G, Carbonnelle C, Raoul H, Coxon R, Abdulla I.A, Hewson R. Development of a Cost - effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. J Infect Dis. 2016;1124-33. https://doi.org/10. 1093/infdis/jiv565
  12. Jarhling P.B, Geisbert J.B, Swearengen J.R, Larsen T, Geiabert T.W. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis. 2007;196(2):400-3. https://doi.org/10.1086/520587
  13. Dowall S.D, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Abdulla I.A, Hewson R, Carroll M.W. Post - exposure treatment of non - human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Scientific Reports 7. 2017;4099:1-15. https://doi.org/10.10 38/s41598-017-03910-7
  14. Донченко В.В., Лебедев В.Н., Маркин В.А., Фирсова И.В. Эффективность вирусспецифических белков в иммуногенезе при экспериментальной лихорадке Марбург. Вопросы вирусологии. 1996;5:216-8.
  15. Краснянский В.П., Михайлов В.В., Борисевич И.В., Градобоев В.Н., Евсеев А.А., Пшеничнов В.А. Получение гипериммунной лошадиной сыворотки против вируса Эбола. Вопросы вирусологии. 1995;40(3):138-40.
  16. Борисевич И.В., Михайлов В.В., Краснянский В.П., Градобоев В.Н., Лебединская Е.В., Потрываева Н.В. Разработка и изучение свойств иммуноглобулина против лихорадки Эбола. Вопросы вирусологии. 1995;40(6):270-3.
  17. Борисевич И.В., Черникова Н.К., Марков В.И., Краснянский В.П., Борисевич С.В., Рождественский Е.В. Опыт применения специфического иммуноглобулина из сыворотки крови лошадей в качестве средства экстренной профилактики лихорадки Эбола. Вопросы вирусологии. 2017;1:25-9. doi: 10.18821/0507-4088-2017-62-1-25-29
  18. Pyankov O.V, Setoch Y.X, Bodnev S.A, Edmonds J.H, Pyankova O.G, Pyankov S.A, Pali G, Belford S, Lu L, La M, Lovrecz G, Volchkova V.A, Chappell K.J, Waterson D, Marsh G, Young P.B, Agafonov A.A, Farmer J.F, Volchkov V.E, Suhbier A, Khromykh A.A. Successful post - exposure prophylaxis of Ebola infected non - human primates using Ebola glycoprotein - specific equine IgG. Scientific Reports. 2017;7:1-8. https://doi.org/ 10.1038/srep.41537
  19. WHO Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Avaiable from: http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguide/en// Accepted Oct.2016.
  20. Dye J.M, Wu H, Hooper J.W, Khurana S, Kuehne A.I, Coile E.M, Ortiz R, Fuentes S, Herbert A.S, Golding H, Bakken R.A, Brannan J.M, Kwilas S.A, Sullivan E.J, Luke T.C, Smith G, Glenn G, Li W, Ye L, Yang C, Compans R.W, Tripp R.A, Jiao J.A. Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle. Scientific Reports 6. 2016;6:1-9. https://doi.org/10.1038/srep 24897
  21. Choi W.Y, Hong K.J, Hong J.E, Lee W.J. Progress of vaccine and drug development for Ebola preparedness. Clin Exp Vaccine Res. 2015;4(1):11-6. https://doi. org/10.7774/cevr.2015.4.1.11
  22. Olinger G.G.Jr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume S.D, Johnson A.K, Morton J, Pauly M, Whaley K.J, Lear C.M, Biggins J.E, Scully C, Hensley L, Zeitlin L. Delayed treatment of Ebola virus infection with plant - derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA. 2012;109(44):18030-5. https://doi.org/10.1073/pnas.1213709109
  23. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong J.E, Plummer F, Corbett C.R, Alimonti J.B, Kobinger G.P. Successful treatment of ebola virus - infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4(138):1-12. https://doi.org/10.1126/scitranslmed.3003876
  24. Haque A, Hober D, Blondiaux J. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother. 2015;59(10):5892-902. https://doi.org/10.1128/aac.01105-15
  25. Sayburn A. WHO gives go ahead for experimental treatments to be used in Ebola outbreak. BMJ. 2014;349:1. https://doi.org/10.1136/bmj.g5161
  26. Zhang Q, Gui M, Niu X, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, Li J, Li C, Shi Y, Shi X, Gao G, Xiang Y, Qiu X, Chen L, Zhang L. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Reports. 2016;6:1-15. https://doi.org/10.1038/srep25856
  27. Holtsberg F.W, Shulenin S, Vu H, Howell K.A, Patel S.J, Gunn B, Karim M, Lai J.R, Frei J.C, Nyakatura E.K, Zeitlin L, Douglas R, Fusco M.L, Froude J.W, Saphire E.O, Herbert A.S, Wirchnianski A.S, Lear-Rooney C.M, Alter G, Dye J.M, Glass P.J, Warfield K.L, Aman M.J. Pan - ebolavirus and Pan - filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J Virol. 2015;90(1):266-78. https://doi.org/10.1128/jvi.02171-15
  28. Keck Z.Y, Enterlein S.G, Howell K.A, Vu H, Shulenin S, Warfield K.L, Froude J.W, Araghi N, Douglas R, Biggins J, Lear-Rooney C.M, Wirchnianski A.S, Lau P, Wang Y, Herbert A.S, Dye J.M, Glass P.J, Holtsberg F.W, Foung S.K.H, Aman M.J. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2016;90(1):279-91. https://doi.org/10.1128/jvi.02172-15
  29. Wec A.Z, Myakatura E.K, Herbert A.S, Howell K.A, Holtsberg F.A, Bakken R.R, Mittler E, Christin J.R, Shulenin S, Jangra R.K, Bharrhan S, Kuehne A.I, Bornholdt Z.A, Flyak A.I, Saphire E.O, Crowe J.E.Jr, Aman M.J, Dye J.M, Lai J.R, Chandran K. A “Trojan horse” bispecific - antibody strategy for broad protection against ebolaviruses. Science. 2016;354(6310):350-4. https://doi.org/10.1126/science.aag 3267

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies